Apotex Corp. Introduces Generic Cetrorelix® Injection in the U.S.

Apotex Corp. has announced the introduction of Cetrorelix Acetate for Injection 0.25mg in the United States. This new product is a generic equivalent of Cetrotide®, designed to inhibit premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. The synthetic decapeptide functions as a gonadotrophin-releasing hormone (GnRH) antagonist.

Christine Baeder, President of Apotex Corp., emphasized the importance of this launch, highlighting that it provides American women with more affordable options for fertility treatments. She noted that this move aligns with Apotex Corp.'s commitment to delivering high-quality medications that are accessible to a broader population.

For detailed information on the usage, warnings, precautions, adverse reactions, and contraindications of Cetrorelix Acetate for Injection, users are advised to consult the complete prescribing information.

Apotex Corp., based in Weston, Florida, is dedicated to offering a variety of affordable and complex medications to patients across the United States. The company and its affiliates globally focus on supplying a comprehensive range of generic, biosimilar, and innovative branded pharmaceutical products.